Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems

Oricell Therapeutics has closed a pre-IPO financing round exceeding $110 million, drawing backing from an international syndicate of investors united by a shared conviction: that CAR-T cell therapy¹, long proven in blood cancers, can finally be made to work in solid tumors.

The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. Additional participants included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital. Proceeds will be directed toward global clinical expansion, platform development, and advancing the company toward capital markets.

Can CAR-T Finally Crack the Solid Tumor Problem?

CAR-T therapies¹ have transformed the treatment of hematologic malignancies, but solid tumors have remained stubbornly resistant. The immunosuppressive

tumor microenvironment, poor T-cell infiltration, and antigen heterogeneity have collectively made solid tumor CAR-T one of the field's most formidable unsolved challenges.

Oricell's approach centers on a proprietary technology triad designed to address these barriers head-on. The Ori®Ab antibody screening and engineering platform identifies and optimizes tumor-targeting antibody fragments, the Ori®Armoring functional enhancement platform is designed to improve CAR-T durability and potency within hostile tumor environments, and the OnGo (Fast) rapid CMC manufacturing platform is built to compress production timelines — a critical factor in autologous cell therapy, where manufacturing speed can directly affect patient outcomes.Together, these three pillars form the foundation of what Oricell calls its integrated "Platform and Pipeline" strategy — one that investors appear to find compelling.

Could Ori-C101 Become the First CAR-T Approved for Liver Cancer?

Oricell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy designed for advanced hepatocellular carcinoma (HCC) — a cancer with historically limited systemic treatment options and poor prognosis in advanced stages. GPC3, a cell-surface protein overexpressed in HCC, serves as the therapeutic target, offering a degree of tumor selectivity that has been difficult to achieve in solid tumor settings.

Ori-C101 has progressed through investigator-initiated trials and a registrational Phase 1 study², with clinical readouts demonstrating what the company describes as a best-in-class efficacy and safety profile. Data have been presented at major scientific forums including the ASCO Annual Meeting. The program is now preparing for pivotal trials, positioning Ori-C101 as a potential first-in-class globally approved CAR-T therapy for HCC — a designation that, if achieved, would mark a historic milestone for the field.

What Does the Next Generation of CAR-T Actually Look Like?

Beyond Ori-C101, Oricell is advancing a portfolio of next-generation modalities that go beyond conventional autologous CAR-T design. These include secreted CAR-T programs, rapid-production formats aimed at reducing manufacturing burden, and — perhaps most ambitiously — in vivo CAR-T, an emerging approach in which the CAR construct is delivered directly into the body to reprogram a patient's own T cells without the need for ex vivo manufacturing altogether.

In vivo CAR-T remains largely pre-clinical across the industry, but its potential to eliminate the logistical and cost challenges of traditional manufacturing has made it one of the most watched frontiers in cell therapy. Oricell's early investment in this modality signals a longer-term vision that extends well beyond its current pipeline.

Safety, Scale, and the Road to Global Markets

The breadth of the investor syndicate — spanning U.S., Chinese, European, and sovereign wealth fund capital — reflects both the global ambition of Oricell's development strategy and the international appetite for cell therapy assets with differentiated clinical data.

"As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepen our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T," said Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics.

If pivotal trial data for Ori-C101 confirms the Phase 1 efficacy and safety signals, Oricell could emerge as one of the first companies to bring a commercially approved solid tumor CAR-T therapy to market — a development that would not only validate its own platform, but potentially redefine what is considered possible in cancer immunotherapy.

References

1. Bruno et al. “CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review” PubMed, December 10, 2024.
   https://pubmed.ncbi.nlm.nih.gov/39495525/
2. Fan et al. “Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC),” ASCO Publications, ASCO Annual Meeting (2025)
   https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.4084